Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SMO Clinplus Co Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for SMO Clinplus Co's Operating Margin % or its related term are showing as below:
SZSE:301257'
s Operating Margin % Range Over the Past 10 Years
Min: 9.36 Med: 16.14 Max: 20.4
Current: 9.36
SZSE:301257's Operating Margin % is ranked better than 68.32% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.085
vs SZSE:301257: 9.36
SMO Clinplus Co's 5-Year Average Operating Margin % Growth Rate was 2.90% per year.
SMO Clinplus Co (SZSE:301257) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
SMO Clinplus Co Operating Margin % Related Terms
SMO Clinplus Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for SMO Clinplus Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301257 vs TMO, DHR, NTRA: Operating Margin % Comparison
For the Diagnostics & Research subindustry, SMO Clinplus Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMO Clinplus Co Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where SMO Clinplus Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
SMO Clinplus Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMO Clinplus Co (SZSE:301257) has a Operating Margin % of -4.56% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on SMO Clinplus Co and its competitors. Over the past decade, SMO Clinplus Co's Operating Margin % has ranged from 9.36 to 20.40. According to the industry distribution chart, SMO Clinplus Co ranks #64 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 31.7%.
Is SMO Clinplus Co's Operating Margin % too high?
SMO Clinplus Co's current Operating Margin % is -4.56%. Over the past 10 years, this metric has ranged from a low of 9.36 to a high of 20.40. Based on the distribution chart, SMO Clinplus Co ranks #64 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SMO Clinplus Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SMO Clinplus Co's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SMO Clinplus Co ranks #64 out of 202 companies for Operating Margin %. This puts SMO Clinplus Co in the upper half of its industry. Historically, SMO Clinplus Co's own Operating Margin % has ranged from 9.36 to 20.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on SMO Clinplus Co and its competitors. SMO Clinplus Co's current Operating Margin % is -4.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMO Clinplus Co stock overvalued right now?
Based on GuruFocus' analysis, SMO Clinplus Co (SZSE:301257) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.90, compared to a current price of ¥35.17 — trading 9.6% below its estimated fair value. The current Operating Margin % is -4.56%. SMO Clinplus Co's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For SMO Clinplus Co (SZSE:301257), the current Operating Margin % is -4.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMO Clinplus Co (SZSE:301257) Overvalued in 2026?
Based on GuruFocus' analysis, SMO Clinplus Co stock appears to be undervalued.
The current stock price of ¥35.17 is trading 9.6% below its estimated GF Value™ of ¥38.90.
GuruFocus considers SMO Clinplus Co to be Modestly Undervalued.
Key valuation signals for SZSE:301257:
Operating Margin %: -4.56%
GF Value™: ¥38.90 vs. price of ¥35.17 (9.6% below fair value)
No single metric tells the full story. See the SZSE:301257 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies, and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
91GF Score
Get the complete analysis for SZSE:301257
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301257 has been successfully added to your 
